Stock Yards Bancorp to Participate in a Series of Investor Meetings
- S&P, Dow futures edge higher ahead of inflation data
- U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death
- Biggest SPAC Deal Ever: Grab To Go Public in a $40 Billion Merger With Altimeter (AGC), Backed by Fidelity and BlackRock
- Oil prices tick up after robust China data
- Bitcoin (BTC) Price Soars 5% to Fresh Record Highs Ahead of Coinbase IPO
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
LOUISVILLE, Ky. , March 11, 2021 (GLOBE NEWSWIRE) -- Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in the Louisville, Indianapolis and Cincinnati metropolitan markets, today announced that James A. (Ja) Hillebrand, Chief Executive Officer, and T. Clay Stinnett, EVP and Chief Financial Officer, will participate in a series of virtual meetings with institutional investors on March 18, 2021, hosted by Raymond James.
Management’s discussion materials to be used at this conference will be posted to the investor section of the Company’s website, www.syb.com, on or before March 18, 2021.
Louisville, Kentucky-based Stock Yards Bancorp, Inc., with $4.6 billion in assets, was incorporated in 1988 as a bank holding company. It is the parent company of Stock Yards Bank & Trust Company, which was established in 1904. The Company’s common shares trade on The NASDAQ Stock Market under the symbol “SYBT.”
|Contact:||T. Clay Stinnett|
|Executive Vice President,|
|Treasurer and Chief Financial Officer|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases
- BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers
- BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases